Thanks, @Idfreedom,
Bigger market bigger opportunity that added $1 billion to Exacts market cap (Yes, $1 billion!!)
Also from a 'Tweeter': "EXACT Sciences (A$9.68B MC) Cologuard needs to be run off a faecal sample. Add to the cost at A$900, compared to <$100 for $RHYs ColoSTAT & it can be added to a panel of blood tests at an annual check-up without its own blood draw, ColoSTAT is likely to be a preferred test."
This why I like RHY... it has all the pillars to be successful, they just need to replicate performance in a larger trial later in the year. Then it is better than existing test (faecal vs blood test) and it is v v cheap relative to the comps... Both market cap and test cost wise viz Colvera (est $200m), Cologuard ($9 billion) etc.
All in all exciting times ahead and as your analysis points to @AMreidIt we are developing a tight register and should see selling dry up volume wise and a rerate shortly.
5x8's
New Feature Announcement!
We’re excited to introduce the DealRoom portal, now live on site, providing users with exciting access to private equity opportunities for both pre-IPO and publicly listed companies.
See full details by selecting the new menu item named 'DealRoom' on our main menu bar or click below.
Stay ahead of the market, with HotCopper.